IL17RD and prostate carcinoma: In a follow-up study on a larger clinical cohort of prostate cancers, the authors reported that IL-17RD is strongly expressed in 74% (32/43 cases) of benign tissues, but in only 21% (37/176 cases) of cancer biopsies.